John R. Mackey

Cancer Research · 2001–2012

A researcher in the Science corpus: 13 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Cancer Research — 43 citations into it
• Molecular Biology — 42 citations into it

Whom John R. Mackey trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Cella
2. Jung-whan Kim
3. Position Stand

Who trusts John R. Mackey overall

1. Kathryn H. Schmitz
2. K. Courneya

Papers from John R. Mackey's perspective

Ordered by how strongly the researchers John R. Mackey trusts endorse each paper. Same corpus, a different order for every researcher.

1. Why do cancers have high aerobic glycolysis? (Nature Reviews. Cancer)
2. Akt Stimulates Aerobic Glycolysis in Cancer Cells (Cancer Research)
3. Multifaceted roles of glycolytic enzymes. (TIBS -Trends in Biochemical Sciences. Regular ed)
4. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. (Cancer Cell)
5. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. (Cell Metabolism)
6. Cancer's molecular sweet tooth and the Warburg effect. (Cancer Research)
7. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. (Cancer Research)
8. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. (Journal of Clinical Oncology)
9. SF-36 health survey: Manual and interpretation guide
10. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. (Journal of Clinical Oncology)

Their papers

• Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer (2008) — 670 citations
• Metabolic Modulation of Glioblastoma with Dichloroacetate (2010) — 753 citations
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers (2012) — 1,975 citations
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer (2011) — 1,412 citations
• Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment (2009) — 1,017 citations
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. (2009) — 854 citations
• Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. (2009) — 627 citations
• Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. (2007) — 1,107 citations
• Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis (2006) — 1,126 citations
• Gastric Adenocarcinoma: Review and Considerations for Future Directions (2005) — 756 citations
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma (2003) — 719 citations
• Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. (2003) — 779 citations
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. (2001) — 922 citations